| Literature DB >> 28053881 |
Roger A Vaughan1, Ailish C White2, Jason R Beam2, Nicholas P Gannon3, Randi Garcia-Smith3, Roy M Salgado2, Marco Bisoffi4, Kristina A Trujillo5, Carole A Conn6, Christine M Mermier2.
Abstract
Obesity is an increasingly prevalent and preventable morbidity with multiple behavioral, surgical and pharmacological interventions currently available. Commercial dietary supplements are often advertised to stimulate metabolism and cause rapid weight and/or fat loss, although few well-controlled studies have demonstrated such effects. We describe a commercially available dietary supplement (purportedly containing caffeine, catechins, and other metabolic stimulators) on resting metabolic rate in humans, and on metabolism, mitochondrial content, and related gene expression in vitro. Human males ingested either a placebo or commercially available supplement (RF) in a randomized double-blind placebo-controlled cross-over fashion. Metabolic rate, respiratory exchange ratio, and blood pressure were measured hourly for 3 h post-ingestion. To investigate molecular effects, human rhabdomyosarcoma cells (RD) and mouse myocytes (C2C12) were treated with various doses of RF for various durations. RF enhanced energy expenditure and systolic blood pressure in human males without altering substrate utilization. In myocytes, RF enhanced metabolism, metabolic gene expression, and mitochondrial content suggesting RF may target common energetic pathways which control mitochondrial biogenesis. RF appears to increase metabolism immediately following ingestion, although it is unclear if RF provides benefits beyond those provided by caffeine alone. Additional research is needed to examine safety and efficacy for human weight loss.Entities:
Keywords: Fat burner; GLUT4, Glucose transporter 4; Mitochondrial biogenesis; NRF-1, Nuclear respiratory factor; Obesity; PGC-1α, Proliferator-activated receptor γ coactivator-1α; Peroxisome proliferator-activated receptor γ coactivator-1α (PGC-1α); REE, Resting energy expenditure; RER, Respiratory exchange ratio; Resting energy expenditure; TBP, TATA Binding Protein; TFAM, Mitochondrial transcription factor A; Thermogenic agent
Year: 2015 PMID: 28053881 PMCID: PMC5198798 DOI: 10.1016/j.jtcme.2015.03.008
Source DB: PubMed Journal: J Tradit Complement Med ISSN: 2225-4110
Purported composition of Ripped Freak®.
| Ripped Freak® Formula 766.6 mg |
|---|
| Methyl EGCG™ (EGCG Derivative Stack) (Green Tea Extract/Camellia Sinensis) |
| Epigallocatechin-3-O-(3-O-Methyl) gallate Ester (EGCG 3′ ′Me) |
| Epigallocatechin-3-O-(4-O-Methyl) gallate Ester (EGCG 4′ ′Me) |
| 4′-O-Methyl-Epigallocatechin-3-O-Gallate Ester (EGCG 4′Me) |
| Epigallocatechin-3-O-(3,4-O-Methyl) gallate Ester (EGCG 3′ ′4′ ′diMe) |
| 4′-O-Methyl-Epigallocatechin-3-O-(4-O-Methyl) gallate Ester (EGCG 4′4′ ′diMe) |
| Oleuropein Aglycone (Olive Leaf Extract/Olea Europaea) |
| 1,3,7-Trimethyl-1H-Purine-2,6(3H,7H)-Dione Methyl Gallate Ester |
| (Caffeine) (Coffee/Coffea Arabica, Whole Bean) |
| CH-19 Sweet Red Pepper Ester Stack |
| (CH-19 Sweet Red Pepper Extract/Capsicum Annum, Fruit) (0.75% Capsiate) |
| 4-Hydroxy-3-Methoxybenzyl (E)-8-Methyl-6-Nonenoate Ester |
| 4-Hydroxy-3-Methoxybenzyl 8-Methyl-Nonanoate Ester |
| 4-Hydroxy-3-Methoxybenzyl 7-Methyl-Octanoate Ester |
| 4-(4-Hydroxyphenyl)-2-Methyl Ethyl Ketone (Raspberry Ketone) |
| 4-(4-Hydroxyphenyl)-2-Butanone Methyl Gallate Ester (Raspberry Ketone – Gallic Acid) |
Percent daily value not established.
Summary of subject (N = 10) anthropometric variables and estimated caffeine consumption.
| Subject variable | Average (±SD) |
|---|---|
| Age (years) | 26.7 (±3.86) |
| Weight (kg) | 77.75 (±8.56) |
| Height (cm) | 175 (±5.0) |
| BMI (kg/m2) | 25.34 (±2.65) |
| Body fat (%) | 14.78 (±6.7) |
| Lean body mass (kg) | 65.97 (±6.05) |
| Caffeine consumption (mg/day) | 292.45 (±150.76) |
Body fat percent was estimated using the Siri equation from 3 site skin fold measurements.
Caffeine intake was estimated through 24 h recall food questionnaire and caffeine content of food and beverage list published by the Mayo Clinic available at: http://www.mayoclinic.com/print/caffeine/AN01211/METHOD=print.
Summary of qRT-PCR primers from Integrated DNA Technologies (Coralville, IA).
| Primer name | Forward sequence | Reverse sequence |
|---|---|---|
| TBPH | 5′-CACGAACCACGGCACTGATT-3′ | 5′-TTTTCTTGCTGCCAGTCTGGAC-3′ |
| PGC-1αH | 5′-ACCAAACCCACAGAGAACAG-3′ | 5′-GGGTCAGAGGAAGAGATAAAGTTG-3′ |
| NRF-1H | 5′-GTATCTCACCCTCCAAACCTAAC-3′ | 5′-CCAGGATCATGCTCTTGTACTT-3′ |
| TFAMH | 5′-GGGAAGGAGGGTTGTGTATTT-3′ | 5′-AGGAGTTAGCCAAACGCAATA-3′ |
| GLUT4H | 5′-AAGAATCCCTGCAGCCTGGTAGAA-3′ | 5′-CCACGGCCAAACCACAACACATAA-3′ |
| TBPM | 5′-GGGATTCAGGAAGACCACATA-3′ | 5′-CCTCACCAACTGTACCATCAG-3′ |
| PGC-1αM | 5′-GACAATCCCGAAGACACTACAG-3′ | 5′-AGAGAGGAGAGAGAGAGAGAGA |
| NRF-1M | 5′-ACCCTCAGTCTCACGACTAT-3′ | 5′-GAACACTCCTCAGACCCTTAAC-3′ |
| TFAMM | 5′-GAAGGGAATGGGAAAGGTAGAG-3′ | 5′-ACAGGACATGGAAAGCAGATTA-3′ |
| GLUT4M | 5′-GGAGGGAGCCTTTGGTATTT-3′ | 5′-CAGGCGAGGACACTCATCTT-3′ |
Abbreviations: peroxisome proliferator-activated receptor gamma coactivator 1 alpha (PGC-1α), nuclear respiratory factor 1 (NRF-1), mitochondrial transcription factor A (TFAM), and glucose transporter 4 (GLUT4) and TATA binding protein (TBP). H indicates for primers for human RNA and M indicates primers for mouse RNA.
Fig. 1Metabolic Rate and Substrate Utilization. (A) Resting energy expenditure (REE) of human male subjects following ingestion of either a placebo (control) or a single serving of RF. (B) Respiratory exchange ratio (RER) of human male subjects following ingestion of either a placebo (control) or a single serving of RF. (C) Systolic blood pressure of human male subjects following ingestion of either a placebo (control) or a single serving of RF. (D) Diastolic blood pressure of human male subjects following ingestion of either a placebo (control) or a single serving of RF. NOTES: * indicates p < 0.05, ** indicates p < 0.01, and *** indicates p < 0.001 compared with control.
Fig. 2Cellular Metabolism. (A) Basal oxidative metabolism indicated by oxygen consumption rate (OCR) of RD (left) cells treated with either ethanol control or RF at 100 μg/ml or 200 μg/ml for 3 or 6 h and C2C12 (right) cells treated with either ethanol control or RF at 10 μg/ml or 20 μg/ml for 3 or 6 h. (B) Peak OCR of RD and C2C12 cells following addition of oligomycin following treatment as described in A. (C) Mitochondrial uncoupling (endogenous mitochondrial proton leak) of RD and C2C12 cells treated as described in A. (D) Basal glycolytic metabolism indicated by extracellular acidification rate (ECAR) of cells treated as described above. (E) Peak ECAR of RD and C2C12 cells following the addition of oligomycin following treatment as described above. (F) Metabolic reliance expressed as a ratio of OCR:ECAR. NOTES: * indicates p < 0.05, ** indicates p < 0.01, and *** indicates p < 0.001 compared with control.
Fig. 3Metabolic Gene Expression. (A) Gene expression of RD cells treated with either ethanol control or RF at 100 μg/ml or 200 μg/ml for 4, 12, or 24 h of PGC-1α, NRF-1, TFAM, and GLUT4. (B) Gene expression of C2C12 cells treated with either ethanol control or RF at 10 μg/ml or 20 μg/ml for 4, 12, or 24 h of PGC-1α, NRF-1, TFAM, and GLUT4. (C) Mitochondrial content indicated by group mean log fluorescence from flow cytometry of RD (left) and C2C12 cells (right) treated as described in methods for 24 h stained with MitoTracker green. (D) Group mean log fluorescence of confocal microscopy of RD cells treated as previously described for 24 h. (E and F) Representative images from fluorescent confocal microscopy of RD cells (E) and C2C12 cells (F) treated as described above. Fluorescent measurements were performed using N = 7 cells/treatment which were stained with MitoTracker (green) and DAPI (blue). (G) Cellular ATP content following treatment of either RD cells (left) or C2C12 cells (right) with RF at various doses for 24 h. NOTES: * indicates p < 0.05, ** indicates p < 0.01, and *** indicates p < 0.001 compared with control. White measurement bar represents 50 μm.